

Troester, S.^{1*}, Schmoellerl, J.², Eder, T.¹, Winter, G.³, Zuber, J.², Grebien, F.¹^{*}Recipient of a DOC Fellowship of the Austrian Academy of Sciences¹Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria | ²Research Institute for Molecular Pathology (IMP), Vienna, Austria | ³CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria


1. INTRODUCTION

NUP98-fusion proteins

- the N-terminal part of *NUP98* is fused to the C-terminal part of ~30 distinct partner genes forming oncogenic fusion proteins
- NUP98-fusion proteins occur in ~5% of pediatric AML patients¹
- >20% of chemotherapy-resistant pediatric AML patients harbor *NUP98* gene rearrangements²
- NUP98-fusion-protein-driven AML is associated with poor prognosis as currently no targeted therapies are available

NUP98-JARID1A

- is the most common NUP98-fusion protein in infant AML
- JARID1A is an H3K4 histone demethylase
- NUP98-fusion proteins are associated with chromatin and regulate gene expression³



dTAG-system for ligand-induced protein degradation


- a heterobifunctional linker molecule binds mutated FKBP12 (=dTAG) fused to a protein of interest⁴
- recruitment of CRBN E3 ubiquitin ligase complex followed by ubiquitination
- fast and inducible proteasomal degradation of a protein of interest

2.HYPOTHESIS


Oncogenic NUP98-fusion proteins are direct transcriptional regulators of target genes that are critical for leukemogenesis.

4.RESULTS


a) Characterization of the dTAG-NUP98-JARID1A cell line




b) Global analysis of changes in nascent mRNA expression upon NUP98-JARID1A degradation by SLAM-seq



c) SLAM-seq data integration with genome-wide loss-of-function CRISPR/Cas9 screen in an NUP98-JARID1A dependent cell line




3. Establishment of a model for ligand-induced degradation of the NUP98-JARID1A fusion protein



5. OUTLOOK

Validation of essential direct transcriptional target genes by inducible shRNA knock-down combined with RNA-seq analysis to recapitulate transcriptional changes induced by NUP98-JARID1A. Investigation of potential core transcriptional regulatory circuit maintained by the fusion protein by super enhancer mapping.



6. CONCLUSIONS

- Development of a model for ligand-induced degradation of the NUP98-JARID1A fusion protein
- Degradation of NUP98-JARID1A leads to cell cycle arrest, differentiation and apoptosis
- Identification of essential direct transcriptional target genes of NUP98-JARID1A & potential therapeutic targets for treatment by SLAM-seq analysis and genome-wide CRISPR/Cas9 screening

References:

- Bisio, V. et al. (2016). NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. *Leukemia*
- McNeer, N. et al. (2019). Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. *Leukemia*
- Schmoellerl, J. et al. (2020). CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. *Blood*
- Nabet, B. et al. (2018). The dTAG system for immediate and target-specific protein degradation. *Nature Chemical Biology*